Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
RemeGen Co. Ltd. Class H ( (HK:9995) ) has issued an announcement.
RemeGen Co., Ltd. has announced a 2025 second class meeting of H shareholders to be held on July 31, 2025. The meeting will address special resolutions including changes to the company’s registered capital, the cancellation of its supervisory committee, and amendments to its Articles of Association and Rules of Procedures for shareholder meetings. These changes may significantly impact the company’s governance structure and operational procedures, potentially affecting its market positioning and stakeholder interests.
The most recent analyst rating on (HK:9995) stock is a Buy with a HK$19.59 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, specializing in the biotechnology industry. The company is focused on developing innovative biopharmaceutical products, primarily targeting areas such as oncology, autoimmune, and ophthalmic diseases.
Average Trading Volume: 12,613,703
Technical Sentiment Signal: Buy
Current Market Cap: HK$38.12B
See more data about 9995 stock on TipRanks’ Stock Analysis page.